These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 28301631)

  • 21. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
    Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
    Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
    BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the androgen receptor in breast cancer.
    Chia K; O'Brien M; Brown M; Lim E
    Curr Oncol Rep; 2015 Feb; 17(2):4. PubMed ID: 25665553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches to targeting the androgen receptor pathway in prostate cancer.
    Velho PI; Bastos DA; Antonarakis ES
    Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen Receptor in Breast Cancer: From Bench to Bedside.
    Chen M; Yang Y; Xu K; Li L; Huang J; Qiu F
    Front Endocrinol (Lausanne); 2020; 11():573. PubMed ID: 32982970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Androgen Receptor: Is It a Promising Target?
    Gucalp A; Traina TA
    Ann Surg Oncol; 2017 Oct; 24(10):2876-2880. PubMed ID: 28766215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
    Austreid E; Lonning PE; Eikesdal HP
    Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
    Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
    Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
    Chia KM; Liu J; Francis GD; Naderi A
    Neoplasia; 2011 Feb; 13(2):154-66. PubMed ID: 21403841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review.
    Choupani E; Mahmoudi Gomari M; Zanganeh S; Nasseri S; Haji-Allahverdipoor K; Rostami N; Hernandez Y; Najafi S; Saraygord-Afshari N; Hosseini A
    Pharmacol Rev; 2023 Mar; 75(2):309-327. PubMed ID: 36781219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
    Edlind MP; Hsieh AC
    Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
    J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.
    Lee SO; Lou W; Hou M; Onate SA; Gao AC
    Oncogene; 2003 Sep; 22(39):7981-8. PubMed ID: 12970746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.